Mecolvix (Mesalazine)

Mesalazine acts locally in the colon by blocking the cyclooxygenase and lipoxygenase enzymes that generate prostaglandins and leukotrienes. By lowering these inflammatory mediators, it diminishes the immune response in the mucosa, leading to reduced swelling, pain, and ulceration associated with inflammatory bowel disease.

The exact dose of Mecolvix is individualized by the prescribing physician based on disease severity, extent of colonic involvement, patient weight, renal and hepatic function, and prior response to therapy. Dosage adjustments are made according to clinical response and tolerability, not by a fixed over‑the‑counter regimen.

Safety data for mesalazine in pregnancy and lactation are limited. The drug is classified as a Category B medication in many regions, indicating that animal studies have not shown risk but human data are insufficient. Clinicians weigh potential benefits against possible risks and may advise discontinuation if safer alternatives exist.

To request Mecolvix, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Both mesalazine (Mecolvix) and sulfasalazine belong to the aminosalicylate class, but mesalazine delivers the active 5‑ASA moiety directly to the colon, often resulting in fewer systemic side effects. Sulfasalazine contains a sulfapyridine component that can cause additional allergic reactions, whereas Mecolvix typically offers a more targeted anti‑inflammatory effect with a better tolerability profile.

Mecolvix should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mecolvix is supplied as a rectal formulation, such as a suppository or enema, and is inserted into the rectum according to the prescribing information. The medication is retained for the period specified by the healthcare provider to allow optimal contact with the colonic mucosa before expulsion.

The most serious adverse events linked to Mecolvix include severe allergic reactions (anaphylaxis, angioedema), blood dyscrasias like leukopenia or thrombocytopenia, and rare cases of pancreatitis or myocarditis. Patients should be instructed to seek immediate medical attention if they experience symptoms such as difficulty breathing, unexplained bruising, or severe abdominal pain.

Mecolvix is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and in those receiving live vaccines where immune response may be compromised.